• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . Live-attenuated pandemic H1N1 influenza vaccines expressing computationally optimized broadly reactive antigens (COBRAs) are immunogenic a

tetano

Editor, Senior Moderator
Vaccine


. 2025 Apr 4:53:127090.
doi: 10.1016/j.vaccine.2025.127090. Online ahead of print. Live-attenuated pandemic H1N1 influenza vaccines expressing computationally optimized broadly reactive antigens (COBRAs) are immunogenic and protective in mice and ferrets

Po-Ling Chen[SUP] 1 [/SUP], Robert A Richardson[SUP] 2 [/SUP], Samuel Rovito[SUP] 1 [/SUP], Guohua Yang[SUP] 1 [/SUP], Haley N Writt[SUP] 1 [/SUP], Chet Ojha[SUP] 1 [/SUP], Jennifer DeBeauchamp[SUP] 1 [/SUP], Jeri Carol Crumpton[SUP] 1 [/SUP], Karlie Woodard[SUP] 1 [/SUP], Melissa Penaflor[SUP] 1 [/SUP], Lisa Kercher[SUP] 1 [/SUP], Richard J Webby[SUP] 1 [/SUP], Giuseppe A Sautto[SUP] 3 [/SUP], Ted M Ross[SUP] 2 [/SUP], Charles J Russell[SUP] 4 [/SUP]



Affiliations
Abstract

Computationally optimized broadly reactive antigens (COBRAs) induce broad and protective immune responses across multiple viral vaccine platforms. However, their suitability for incorporation into live attenuated influenza vaccines (LAIVs) remains uncertain, as antigen modifications could potentially impact LAIV generation, replication, stability, or immunogenicity. In this study, COBRA hemagglutinin (HA) and neuraminidase (NA) antigens designated Y2 and N1I, respectively, of the influenza H1N1 subtype were reverse-engineered into A/Puerto Rico/8/1934 (PR8)-based LAIVs. The impact of HA stability and NA composition on LAIV properties was evaluated in cell culture, mice, and ferrets. COBRA LAIV yields were higher in MDCK cells compared to Vero cells, and a higher HA activation pH was associated with increased LAIV growth in cell culture. The COBRA LAIVs elicited broad antibody responses against pandemic H1N1 viruses and provided robust protection in both mice and ferrets. The standard COBRA LAIV, containing unmodified HA Y2 and NA N1I, had virus inactivation pH and HA activation pH values of 5.4 and 5.6, respectively. In contrast, a modified COBRA LAIV, containing an HA2-K153E mutation and NA from the vaccine strain A/Hawaii/70/2019 (HI19), had a virus inactivation pH of 5.3 and an elevated HA activation pH of 6.0. This modified LAIV had improved growth in cell culture and greater protection from challenge virus lung titers in elderly ferrets. These studies demonstrate the successful integration of COBRA antigen engineering into a LAIV platform. Furthermore, fine-tuning HA stability and NA composition appears to be a promising strategy to enhance LAIVs containing modifications to computationally optimized antigens.

Keywords: Antigen engineering; Computational biology; Hemagglutinin; Influenza virus; Live attenuated vaccine; Stability.

 
Back
Top Bottom